Literature DB >> 34071045

Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas.

Piotr Donizy1, Cheng-Lin Wu2, Janusz Kopczynski3, Malgorzata Pieniazek4, Przemyslaw Biecek5, Janusz Ryś6, Mai P Hoang7.   

Abstract

The association of immune markers and clinicopathologic features and patient outcome has not been extensively studied in Merkel cell carcinoma (MCC). We correlated tumoral PD-L1 and IDO1 expression, and intratumoral CD8+ and FoxP3+ lymphocytes count with clinicopathologic variables, Merkel cell polyomavirus (MCPyV) status, and patient outcomes in a series of 132 MCC. By univariate analyses, tumoral PD-L1 expression >1% and combined tumoral PD-L1 >1% and high intratumoral FoxP3+ lymphocyte count correlated with improved overall survival (OS) (p = 0.016, 0.0072), MCC-specific survival (MSS) (p = 0.019, 0.017), and progression-free survival (PFS) (p = 0.043, 0.004, respectively). High intratumoral CD8+ and FoxP3+ lymphocyte count correlated with longer MSS (p = 0.036) and improved PFS (p = 0.047), respectively. Ulceration correlated with worse OS and worse MSS. Age, male gender, and higher stage (3 and 4) significantly correlated with worse survival. MCPyV positivity correlated with immune response. By multivariate analyses, only ulceration and age remained as independent predictors of worse OS; gender and stage remained for shorter PFS. Tumoral PD-L1 expression and increased density of intratumoral CD8+ lymphocytes and FoxP+ lymphocytes may represent favorable prognosticators in a subset of MCCs. Tumoral PD-L1 expression correlated with intratumoral CD8+ and FoxP3+ lymphocytes, which is supportive of an adaptive immune response.

Entities:  

Keywords:  CD8; FoxP3; IDO1; Merkel cell carcinoma; PD-L1

Year:  2021        PMID: 34071045     DOI: 10.3390/ijms22115489

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  27 in total

1.  Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.

Authors:  Laurence Feldmeyer; Courtney W Hudgens; Genevieve Ray-Lyons; Priyadharsini Nagarajan; Phyu P Aung; Jonathan L Curry; Carlos A Torres-Cabala; Barbara Mino; Jaime Rodriguez-Canales; Alexandre Reuben; Pei-Ling Chen; Jennifer S Ko; Steven D Billings; Roland L Bassett; Ignacio I Wistuba; Zachary A Cooper; Victor G Prieto; Jennifer A Wargo; Michael T Tetzlaff
Journal:  Clin Cancer Res       Date:  2016-05-10       Impact factor: 12.531

2.  A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma.

Authors:  Noreen M Walsh; Kirsten E Fleming; John G Hanly; Kelly Dakin Hache; Steve Doucette; Gerardo Ferrara; Lorenzo Cerroni
Journal:  Hum Pathol       Date:  2016-03-02       Impact factor: 3.466

3.  Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.

Authors:  Kelly G Paulson; Jayasri G Iyer; Andrew R Tegeder; Renee Thibodeau; Janell Schelter; Shinichi Koba; David Schrama; William T Simonson; Bianca D Lemos; David R Byrd; David M Koelle; Denise A Galloway; J Helen Leonard; Margaret M Madeleine; Zsolt B Argenyi; Mary L Disis; Juergen C Becker; Michele A Cleary; Paul Nghiem
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

Review 4.  The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.

Authors:  Lieve Brochez; Ines Chevolet; Vibeke Kruse
Journal:  Eur J Cancer       Date:  2017-03-18       Impact factor: 9.162

5.  Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study.

Authors:  Harri Sihto; Tom Böhling; Heli Kavola; Virve Koljonen; Marko Salmi; Sirpa Jalkanen; Heikki Joensuu
Journal:  Clin Cancer Res       Date:  2012-03-30       Impact factor: 12.531

6.  High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.

Authors:  Jocelyne Jacquemier; François Bertucci; Pascal Finetti; Benjamin Esterni; Emmanuelle Charafe-Jauffret; Marie-Laure Thibult; Gilles Houvenaeghel; Benoit Van den Eynde; Daniel Birnbaum; Daniel Olive; Luc Xerri
Journal:  Int J Cancer       Date:  2012-01-01       Impact factor: 7.396

7.  PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Authors:  Paul T Nghiem; Shailender Bhatia; Evan J Lipson; Ragini R Kudchadkar; Natalie J Miller; Lakshmanan Annamalai; Sneha Berry; Elliot K Chartash; Adil Daud; Steven P Fling; Philip A Friedlander; Harriet M Kluger; Holbrook E Kohrt; Lisa Lundgren; Kim Margolin; Alan Mitchell; Thomas Olencki; Drew M Pardoll; Sunil A Reddy; Erica M Shantha; William H Sharfman; Elad Sharon; Lynn R Shemanski; Michi M Shinohara; Joel C Sunshine; Janis M Taube; John A Thompson; Steven M Townson; Jennifer H Yearley; Suzanne L Topalian; Martin A Cheever
Journal:  N Engl J Med       Date:  2016-04-19       Impact factor: 91.245

8.  Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma.

Authors:  Lusi Oka Wardhani; Michiko Matsushita; Takeshi Iwasaki; Satoshi Kuwamoto; Daisuke Nonaka; Keiko Nagata; Masako Kato; Yukisato Kitamura; Kazuhiko Hayashi
Journal:  Hum Pathol       Date:  2018-09-18       Impact factor: 3.466

9.  Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses.

Authors:  Mitra Dowlatshahi; Victor Huang; Ahmed E Gehad; Ying Jiang; Adam Calarese; Jessica E Teague; Andrew A Dorosario; Jingwei Cheng; Paul Nghiem; Carl F Schanbacher; Manisha Thakuria; Chrysalyne D Schmults; Linda C Wang; Rachael A Clark
Journal:  J Invest Dermatol       Date:  2013-02-18       Impact factor: 8.551

10.  Distinct gene expression profiles of viral- and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis.

Authors:  Paul W Harms; Rajiv M Patel; Monique E Verhaegen; Thomas J Giordano; Kevin T Nash; Craig N Johnson; Stephanie Daignault; Dafydd G Thomas; Johann E Gudjonsson; James T Elder; Andrzej A Dlugosz; Timothy M Johnson; Douglas R Fullen; Christopher K Bichakjian
Journal:  J Invest Dermatol       Date:  2012-12-06       Impact factor: 8.551

View more
  2 in total

Review 1.  Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment.

Authors:  Glauco Akelinghton Freire Vitiello; Wallax Augusto Silva Ferreira; Vladmir Cláudio Cordeiro de Lima; Tiago da Silva Medina
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

2.  Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma.

Authors:  T Gambichler; S Said; N Abu Rached; C H Scheel; L Susok; R Stranzenbach; J C Becker
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-31       Impact factor: 4.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.